Low Dose Cytarabine

DRUG4 trials

Sponsors

Seagen Inc., Hospital Israelita Albert Einstein, Jianxiang Wang, Foghorn Therapeutics Inc.

Conditions

Acute Myeloid LeukemiaAdvanced Hematologic MalignancyMyelodysplastic SyndromesMyeloproliferative NeoplasmsMyeloproliferative/Myelodysplastic NeoplasmRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndromes

Phase 1

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Active, not recruitingNCT04891757

Foghorn Therapeutics Inc.Advanced Hematologic Malignancy, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia +4

Start: 2021-06-14End: 2027-06-30Target: 144Updated: 2025-07-10

Phase 2

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

CompletedNCT00528333

Seagen Inc.Acute Myeloid Leukemia

Start: 2007-09-30End: 2010-08-31Updated: 2015-01-07

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

CompletedNCT02084563

Hospital Israelita Albert EinsteinAcute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative/Myelodysplastic Neoplasm +1

Start: 2012-10-31End: 2016-11-30Updated: 2016-11-08

Unknown Phase

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old

Jianxiang WangAcute Myeloid Leukemia

Start: 2015-04-30End: 2021-05-31Target: 300Updated: 2016-10-07

Related Papers

Genomic and phenotypic impact of FHD-286–induced inhibition of SMARCA4/2 in patients with relapsed/refractory myeloid malignancies

Blood2025-11-03

Machine learning-powered integration of global proteomics and ex vivo sensitivity unveils a protein signature predictive of treatment success to AML therapy: Validation in patients treated with FHD-286, a SMARCA2/4 dual inhibitor

Blood2025-11-03

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research2025-04-165 citations

Preclinical efficacy of BRG1/BRM ATPase inhibitor in B lymphoblastic leukemia.

Journal of Clinical Oncology2024-06-011 citations

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Blood2023-11-0220 citations

888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models

Regular and Young Investigator Award Abstracts2022-11-012 citations

Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML

Cancer Research2022-06-15